Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,661 across all filing types
Latest filing 2021-04-28 Capital/Financing Update
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
''Morepen Group seals $100mn (Rs. 750 crores approx.) investment from Corinth Group of Switzerland'
Capital/Financing Update Classification · 95% confidence The document is a press release announcing a significant investment of $100 million by Corinth Group into Morepen Laboratories Limited. It details the investment amount, share allotment, use of funds, and strategic plans. There are no financial statements, quarterly or annual results, nor is this a regulatory filing or certification. The content focuses on capital infusion and financing activities, including share allotment and preferential issuance. Therefore, this document fits the category of Capital/Financing Update (CAP). The document length is substantial and contains detailed information about the financing event, not just an announcement of a report or a brief notification.
2021-04-28 English
The Board of Directors of the Company, in their meeting held on Wednesday, 28th April 2021 have, inter-alia, subject to approval of members of the Company, considered and approved issue ....
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board Meeting held on April 28, 2021. It announces the Board's approval for a preferential issue and allotment of equity shares to specific investors, including details on the number of shares, pricing, and regulatory compliance under SEBI (ICDR) Regulations, 2018. The document also mentions an upcoming Extraordinary General Meeting to seek shareholder approval for the preferential issue. The content focuses on capital raising activities and changes in the company's capital structure through preferential allotment of shares. There are no financial statements or detailed financial performance data, so it is not an Annual or Interim Report. It is not a simple announcement of a report publication but a substantive update on financing activity. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2021-04-28 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to stock exchanges (NSE and BSE) regarding the outcome of a Board Meeting held on April 28, 2021. It announces the Board's approval for a preferential issue and allotment of equity shares to specific investors, including details on the number of shares, pricing, and regulatory compliance under SEBI (ICDR) Regulations. It also mentions an upcoming Extraordinary General Meeting to seek shareholder approval for the preferential issue. The content focuses on capital raising activities and changes in the company's capital structure rather than financial results, management changes, or regulatory certifications. The document length is 7,439 characters, which is sufficient to contain substantive information about the capital issuance. Therefore, this filing is best classified as a Capital/Financing Update (CAP).
2021-04-28 English
Updates
Regulatory Filings Classification · 95% confidence The document is an intimation letter addressed to stock exchanges (NSE and BSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a legal/regulatory development where the Securities Appellate Tribunal quashed a prior SEBI order restraining the company from securities market activities. The document is a regulatory announcement about a legal/regulatory matter, not a financial report, audit, or management discussion. It is short (1914 characters) and serves as a formal notification to the stock exchanges. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-04-26 English
This is to you inform you that Hon'ble Securities Appellate Tribunal ('SAT') by an order pronounced on 15th April 2021 (hosted on website of the SAT on 24th April 2021), quashed and set ....
Regulatory Filings Classification · 95% confidence The document is an intimation letter addressed to stock exchanges (NSE and BSE) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It informs about a legal/regulatory development where the Securities Appellate Tribunal quashed a prior SEBI order restraining the company from securities market activities. The document is short (1914 characters) and serves as a regulatory announcement rather than a detailed report or financial statement. It does not contain financial data, audit information, or detailed management discussion. It is not a report publication announcement since it does not mention any report being published or attached. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement and compliance update.
2021-04-25 English
Board Meeting — Fund Raising
Board/Management Information Classification · 95% confidence The document is a notification addressed to stock exchanges about an upcoming Board of Directors meeting scheduled to consider fundraising proposals. It references Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, which pertains to board meeting disclosures. The content is an announcement of a board meeting and its agenda, not the meeting materials or minutes themselves. The document is short (2107 characters) and serves as an intimation rather than a detailed report or presentation. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or meetings of the board or senior management.
2021-04-24 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.